PharmaCyte Biotech, Inc.
PMCB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PMCB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PMCB
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company developing a cell encapsulation therapy for locally advanced pancreatic cancer (LAPC), currently under an FDA clinical hold and working to resolve manufacturing and preclinical requirements.
Key risk: FDA clinical hold unresolved
Market Cap
$5.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Apr 30, 2026.
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company developing a cell encapsulation therapy for locally advanced pancreatic cancer (LAPC), currently under an FDA clinical hold and working to resolve manufacturing and preclinical requirements.
- Cash and equivalents of $18.6M and shareholders' equity of $51.9M as of 2026-04-30 [sec].
- The company's planned clinical trial in LAPC remains under FDA clinical hold; management is actively working to complete FDA-required tasks to lift the hold [sec_mda · as of 2026-07-29].
- PharmaCyte is in ongoing dialogue with SG Austria to prepare syringes filled with the latest generation of CypCaps™ for preclinical studies [sec_mda · as of 2026-03-17].
- The company believes the technology (intra-arterial chemotherapy) has been used in five human clinical trials and that data from those trials may supersede the need for a large animal study [sec_mda · as of 2025-09-15].
What works
- Cash position of $18.6M as of 2026-04-30 provides a runway of at least twelve months from the latest filing date [sec_mda · as of 2026-03-17].
- The company has raised capital through a Series C convertible preferred stock private placement, generating $7M in gross proceeds in August 2025 [sec_mda · as of 2025-12-18].
- Management is actively engaging with the FDA and SG Austria to advance the CypCaps™ manufacturing and regulatory pathway [sec_mda · as of 2026-03-17].
What to weigh
- The IND for the LAPC trial remains under clinical hold, with no publicly disclosed timeline for resolution [sec_mda · as of 2026-07-29].
- The company faces significant regulatory and manufacturing hurdles, including completing all FDA-required tasks and producing genetically modified encapsulated cells [sec_mda · as of 2026-07-29].
- PharmaCyte has an accumulated deficit and no approved products or revenue from operations, relying entirely on capital raises for funding [sec_mda · as of 2025-12-18].
From the filings
Quoted directly from source documents.
The company must complete FDA-required tasks to lift the clinical hold on its IND for the LAPC trial.
“complete all of the tasks the FDA requires of us in order to have the clinical hold lifted; and (viii) obtain approval from the FDA to lift the clinical hold on our IND that we may commence our planned clinical trial in LAPC.”
SEC MD&A · July 29, 2026
PharmaCyte is preparing syringes with the latest CypCaps™ for preclinical studies.
“We are in ongoing dialogue with SG Austria to prepare for the next steps, including the preparation of the syringes filled with the latest generation of CypCaps™ with the working cell bank material.”
SEC MD&A · March 17, 2026
The company believes human clinical trial data may eliminate the need for a large animal study.
“Our position is that the data available from these human clinical trials supersedes large animal study data.”
SEC MD&A · September 15, 2025
Cash and equivalents were approximately $20.2M as of January 31, 2026.
“As of January 31, 2026, we had approximately $20.2 million in cash and cash equivalents”
SEC MD&A · March 17, 2026
Risks & what to watch (4)›
Key risks
- FDA clinical hold unresolved — The IND for the LAPC trial remains under clinical hold with no set timeline for resolution [sec_mda · as of 2026-07-29].
- Dependence on capital raises — The company has no approved products or revenue and relies on equity offerings for funding [sec_mda · as of 2025-12-18].
- Manufacturing and regulatory hurdles — Producing genetically modified encapsulated cells and completing all FDA-required tasks are complex and uncertain [sec_mda · as of 2026-07-29].
- Potential need for additional studies — The FDA may require additional preclinical studies beyond those currently planned [sec_mda · as of 2025-12-18].
What to watch
- FDA response on the clinical hold and any required preclinical studies [sec_mda · as of 2026-07-29].
- Progress in preparing CypCaps™ syringes with SG Austria for preclinical work [sec_mda · as of 2026-03-17].
- Cash burn rate and any future capital raises or financing activities [sec_mda · as of 2026-03-17].
- Updates on the company's ability to complete all FDA-required tasks and lift the clinical hold [sec_mda · as of 2026-07-29].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run PharmaCyte Biotech, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PharmaCyte Biotech, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$743K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 519,747 | $346K |
| geode capital management, llc | 195,660 | $130K |
| vanguard capital management llc | 102,934 | $68K |
| renaissance technologies llc | 56,500 | $38K |
| xtx topco ltd | 52,362 | $35K |
| northern trust corp | 35,601 | $24K |
| schonfeld strategic advisors llc | 27,009 | $18K |
| vanguard fiduciary trust co | 23,452 | $16K |
| equitec proprietary markets, llc | 22,227 | $15K |
| simplex trading, llc | 19,940 | $13K |
Showing top 10 of 31 institutional holders of PharmaCyte Biotech, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 21, 2026- % of float
- 1.0%
- Days to cover
- 0.6
- Shares short
- 97,390
- Daily short volume (May 20, 2026)
- 22.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PMCB short interestGovernance
Frequently asked questions
What is the AI investment thesis for PharmaCyte Biotech, Inc.?
PharmaCyte Biotech, Inc. is a clinical-stage biotechnology company developing a cell encapsulation therapy for locally advanced pancreatic cancer (LAPC), currently under an FDA clinical hold and working to resolve manufacturing and preclinical requirements.
Who is the CEO of PharmaCyte Biotech, Inc.?
Mr. Joshua N. Silverman is the chief executive officer of PharmaCyte Biotech, Inc. (PMCB).
Where is PharmaCyte Biotech, Inc. headquartered?
PharmaCyte Biotech, Inc. (PMCB) is headquartered in Las Vegas, NV, United States.
What therapeutic areas does PharmaCyte Biotech, Inc. focus on?
PharmaCyte Biotech, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.